Stocks and Investing Stocks and Investing
Fri, February 16, 2024
Thu, February 15, 2024

Kristen Kluska Reiterated (SRPT) at Hold and Held Target at $128 on, Feb 15th, 2024


Published on 2024-10-28 09:00:30 - WOPRAI, Kristen Kluska
  Print publication without navigation


Kristen Kluska of Cantor Fitzgerald, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Hold and Held Target at $128 on, Feb 15th, 2024.

Kristen has made no other calls on SRPT in the last 4 months.



There are 10 other peers that have a rating on SRPT. Out of the 10 peers that are also analyzing SRPT, 0 agree with Kristen's Rating of Hold.



These are the ratings of the 10 analyists that currently disagree with Kristen


  • Uy Ear of "Mizuho" Maintained at Strong Buy with Increased Target to $145 on, Wednesday, February 14th, 2024
  • Kostas Biliouris of "BMO Capital" Initiated at Buy and Held Target at $170 on, Wednesday, January 31st, 2024
  • Andreas Argyrides of "Wedbush" Reiterated at Buy and Held Target at $224 on, Tuesday, January 30th, 2024
  • Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $140 on, Monday, January 29th, 2024
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $151 on, Thursday, January 25th, 2024
  • David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $113 on, Wednesday, December 13th, 2023
  • Neena Bitritto-Garg of "Deutsche Bank" Initiated at Strong Buy and Held Target at $109 on, Tuesday, December 12th, 2023
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $141 on, Thursday, November 2nd, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $115 on, Tuesday, October 31st, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $146 on, Tuesday, October 31st, 2023
Contributing Sources